Physician profile
David M Celestial
NPI 1982691952
$10,924.87
in general payments reported to CMS, 2019-2025
40 companies · $1,789 in 2025
The $1,789 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,246 · 2020: $1,058 · 2021: $1,460 · 2022: $1,467 · 2023: $1,879 · 2024: $2,025 · 2025: $1,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,694.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,543.21 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,510.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,298.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,029.30 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $903.86 | 2021-2025 | |
| Glaxosmithkline, LLC. | $846.15 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $496.71 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $474.69 | 2019-2023 | |
| Pfizer INC. | $430.97 | 2019-2025 | |
| Abbott Laboratories | $374.60 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $311.97 | 2019-2022 | |
| Amgen INC. | $307.23 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $219.18 | 2021-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $213.84 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $108.71 | 2022-2025 | Rexulti |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Celestial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.